HOPKINTON, Mass., Dec. 7 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Kenneth L. Rice Jr., Executive Vice President and Chief Financial Officer of Alseres Pharmaceuticals, Inc., will be presenting a company overview at the New York Society of Security Analysts' 11th Annual Biotech/Specialty Pharma Conference, December 12th, 2007.
The New York Society of Security Analysts' 11th Annual Biotech/Specialty Pharma Conference hosts many of the industry's most innovative small- and micro-cap companies to discuss their plans to invent, develop, research and market important new drugs, diagnostics and delivery technologies. For more information on the conference and speaking companies please go to http://www.nyssa.org. Alseres' presentation will not be web cast at this conference.
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company
engaged in developing breakthrough regenerative therapeutics to treat
traumatic injuries and degenerative diseases. The Company maintains a
world-class intellectual property position in the field of regenerative
therapeutics. Our energy and focus is reflected in several important
initiatives. Cethrin(R) is a recombinant-protein-based drug designed to
promote nerve repair after acute spinal cord injury. Cethrin has
demonstrated positive interim results in a Phase I/IIa clinical trial. The
Company's research and pre-clinical programs include, Inosine for the
treatment of spinal cord injury and stroke, Oncomodulin for the treatment
of ocular injury and disease and research programs directed at a number of
regenerative therapies including bone repair. The Company has a robust
molecular imaging development program targeting diagnosis of Parkinson's
disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular
imaging candidate, is in Phase III clinical trials for the diagnosis of
Parkinson's disease. Alseres has research collaborations with Harvard
Medical School and Children's Hospital Boston.
Contact: Sharon Correia
Director, Corporate Communications
508-497-2360 ext. 224
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved